Literature DB >> 12077222

Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins.

Osamu Takeuchi1, Shintaro Sato, Takao Horiuchi, Katsuaki Hoshino, Kiyoshi Takeda, Zhongyun Dong, Robert L Modlin, Shizuo Akira.   

Abstract

The Toll-like receptor (TLR) family acts as pattern recognition receptors for pathogen-specific molecular patterns (PAMPs). TLR2 is essential for the signaling of a variety of PAMPs, including bacterial lipoprotein/lipopeptides, peptidoglycan, and GPI anchors. TLR6 associates with TLR2 and recognizes diacylated mycoplasmal lipopeptide along with TLR2. We report here that TLR1 associates with TLR2 and recognizes the native mycobacterial 19-kDa lipoprotein along with TLR2. Macrophages from TLR1-deficient (TLR1(-/-)) mice showed impaired proinflammatory cytokine production in response to the 19-kDa lipoprotein and a synthetic triacylated lipopeptide. In contrast, TLR1(-/-) cells responded normally to diacylated lipopeptide. TLR1 interacts with TLR2 and coexpression of TLR1 and TLR2 enhanced the NF-kappaB activation in response to a synthetic lipopeptide. Furthermore, lipoprotein analogs whose acylation was modified were preferentially recognized by TLR1. Taken together, TLR1 interacts with TLR2 to recognize the lipid configuration of the native mycobacterial lipoprotein as well as several triacylated lipopeptides.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12077222     DOI: 10.4049/jimmunol.169.1.10

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  388 in total

1.  Enhancing antitumor immunity perioperatively: a matter of timing, cooperation, and specificity.

Authors:  Jeffrey L Curtis; Antonello Punturieri
Journal:  Am J Respir Cell Mol Biol       Date:  2003-05       Impact factor: 6.914

Review 2.  Role of TLR2-dependent inflammation in metastatic progression.

Authors:  Sunhwa Kim; Michael Karin
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

Review 3.  Role of Toll-like receptors in pathogen recognition.

Authors:  S Janssens; R Beyaert
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

4.  Mitogenicity of the recombinant mycobacterial 27-kilodalton lipoprotein is not connected to its antiprotective effect.

Authors:  Avi-Hai Hovav; Liuba Davidovitch; Gabriel Nussbaum; Jacob Mullerad; Yolanta Fishman; Herve Bercovier
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

5.  Identification of novel synthetic toll-like receptor 2 agonists by high throughput screening.

Authors:  Yue Guan; Katherine Omueti-Ayoade; Sarita K Mutha; Paul J Hergenrother; Richard I Tapping
Journal:  J Biol Chem       Date:  2010-05-26       Impact factor: 5.157

6.  A novel aminosaccharide compound blocks immune responses by Toll-like receptors and nucleotide-binding domain, leucine-rich repeat proteins.

Authors:  Kyoung-Hee Lee; Yuen-Joyce Liu; Amlan Biswas; Chikako Ogawa; Koichi S Kobayashi
Journal:  J Biol Chem       Date:  2010-12-07       Impact factor: 5.157

Review 7.  Immunogenomics and systems biology of vaccines.

Authors:  Luigi Buonaguro; Bali Pulendran
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

8.  Mycobacterium tuberculosis Lipoprotein and Lipoglycan Binding to Toll-Like Receptor 2 Correlates with Agonist Activity and Functional Outcomes.

Authors:  Supriya Shukla; Edward T Richardson; Michael G Drage; W Henry Boom; Clifford V Harding
Journal:  Infect Immun       Date:  2018-09-21       Impact factor: 3.441

9.  A novel class of lipoprotein lipase-sensitive molecules mediates Toll-like receptor 2 activation by Porphyromonas gingivalis.

Authors:  Sumita Jain; Stephen R Coats; Ana M Chang; Richard P Darveau
Journal:  Infect Immun       Date:  2013-02-04       Impact factor: 3.441

10.  Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy.

Authors:  Amanda Shanks Huynh; Woo Jin Chung; Hyun-Il Cho; Valerie E Moberg; Esteban Celis; David L Morse; Josef Vagner
Journal:  J Med Chem       Date:  2012-11-08       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.